Q-omics provides the consensus-scored CHCHD2P6 profile across patient tissues and cancer cell-line models. CHCHD2P6 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CHCHD2P6 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, CHCHD2P6 RNA expression shows 17,179 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where CHCHD2P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHCHD2P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHCHD2P6 survival associations across molecular data types. CHCHD2P6 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHCHD2P6 RNA expression–survival associations across cancer types. High CHCHD2P6 expression shows unfavorable associations in ACC and LGG, but favorable associations in KIRC, PAAD, SKCM and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CHCHD2P6 RNA expression.
This table summarizes CHCHD2P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CHCHD2P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHCHD2P6 shows lower tumor expression in THCA and KICH and higher tumor expression in COAD, LIHC, HNSC and BLCA. The THCA box plot shows higher CHCHD2P6 RNA expression in normal versus tumor tissue (log2 FC = −1.062, t-test p < 0.001).
This table shows molecular features associated with CHCHD2P6 in patient tissues and cancer cell lines. In patient samples, CHCHD2P6 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
